Table 1.
Summary of the clinical trials mentioned in the review.
| Trial ID | Target | Combination Therapy | Phase | Tumor Disease | Ref. |
|---|---|---|---|---|---|
| Tumor vasculature | |||||
| NCT04191889 | Apatinib (anti-VEGFR-2) | Camrelizumab (anti-PD-1) | II | Hepatocellular carcinoma | [168] |
| NCT04047017 | Apatinib (anti-VEGFR-2) | Camrelizumab (anti-PD-1) | II | High-risk chemorefractory or relapsed gestational trophoblastic neoplasia | [169] |
| NCT03603756 | Apatinib (anti-VEGFR-2) | Camrelizumab (anti-PD-1), Chemotherapy | II | Advanced esophageal squamous cell carcinoma | [170] |
| NCT03092895 | Apatinib (anti-VEGFR-2) | Camrelizumab (anti-PD-1) | Ib/II | Advanced primary liver cancer | [171] |
| NCT02588170 | Sulfatinib (anti-VEGFR-1/2/3) | no | III | Advanced neuroendocrine tumor | [172] |
| NCT02314819 | Fruquintinib (anti-VEGFR-1/2/3) | no | III | Metastatic colorectal cancer | [173] |
| NCT02811861 | Lenvatinib (anti-VEGFR-1/2/3) | Pembrolizumab (anti-PD-1) | III | Advanced renal carcinoma | [182] |
| NCT05281471 | Bevacizumab (anti-VEGFR-1/2/3) | Chemotherapy | III | Platinum-resistant/refractory ovarian cancer | [183] |
| NCT03038100 | Bevacizumab (anti-VEGFR-1/2/3) | Atezolizumab (anti-PD-L1), Chemotherapy | III | Stage III or IV Ovarian Cancer | [184] |
| CXCR4-CXCL12 axis | |||||
| NCT00903968 | Plerixafor (anti-CXCR4) | Chemotherapy | I/II | Multiple myeloma | [186] |
| NCT02826486 | Motixafortide (anti-CXCR4) | Chemotherapy | II | Pancreatic cancer | [187] |
| NCT01837095 | Balixafortide (anti-CXCR4) | Chemotherapy | I | HER2-negative metastatic breast cancer | [188] |
| NCT01439568 | LY2510924 (anti-CXCR4) | Chemotherapy | II | Extensive-disease small cell lung cancer | [189] |
| NCT01391130 | LY2510924 (anti-CXCR4) | Sunitinib (anti-multiple receptor tyrosine kinases) | II | Metastatic Renal Cell Carcinoma | [190] |